Resource Library
Strategic biomanufacturing framework and technologies for successful partnership
While industry demands grow, biomanufacturing capacity expansion must be accompanied by enhanced technologies and capabilities to meet the evolving needs of complex molecules. The latest whitepaper highlights Samsung Biologics' key competitive advantages that a reliable CDMO possesses to enable the highest quality and accelerate success. Read more
Managing surging demand for biomanufacturing capacity
In an increasingly complex biopharmaceutical landscape, one where manufacturing demand grows year over year, identifying manufacturing capacity that can adapt to the needs of specific portfolios is crucial for success. According to Fortune Business Insights, the world’s biopharmaceutical sector is projected to grow from $616.94 billion in 2024 to $1,183.72 billion by 2032. This projected market growth underscores the sector’s many advances in recent years.
Flexible capacity drug manufacturing
Many contract manufacturing organizations (CMOs) have begun expanding their capacity in response to rising demand, but this alone is not enough to bridge the gap for the bioprocessing industry. Ultimately, identifying the right capacity, capabilities, and technical or operational expertise to best serve a portfolio comes down to evaluating a CMO’s strengths across the following five key pillars:
- Capacity that can adapt to customers’ changing needs and provide scale-up strategies
- Agility that enables swift project execution and optimizes timelines
- Flexibility centered on successful facility fit for a range of complex molecules and processes
- Efficiency that consistently prioritizes risk-based, phase-appropriate maintenance and validation
- Technology innovation poised to boost productivity and improve facility use, as well as support comprehensive laboratory and manufacturing services
In this whitepaper, we explore each of these pillars in more detail.
While industry demands grow, biomanufacturing capacity expansion must be accompanied by enhanced technologies and capabilities to meet the evolving needs of complex molecules. The latest whitepaper highlights Samsung Biologics' key competitive advantages that a reliable CDMO possesses to enable the highest quality and accelerate success. Read more
Managing surging demand for biomanufacturing capacity
In an increasingly complex biopharmaceutical landscape, one where manufacturing demand grows year over year, identifying manufacturing capacity that can adapt to the needs of specific portfolios is crucial for success. According to Fortune Business Insights, the world’s biopharmaceutical sector is projected to grow from $616.94 billion in 2024 to $1,183.72 billion by 2032. This projected market growth underscores the sector’s many advances in recent years.
Flexible capacity drug manufacturing
Many contract manufacturing organizations (CMOs) have begun expanding their capacity in response to rising demand, but this alone is not enough to bridge the gap for the bioprocessing industry. Ultimately, identifying the right capacity, capabilities, and technical or operational expertise to best serve a portfolio comes down to evaluating a CMO’s strengths across the following five key pillars:
- Capacity that can adapt to customers’ changing needs and provide scale-up strategies
- Agility that enables swift project execution and optimizes timelines
- Flexibility centered on successful facility fit for a range of complex molecules and processes
- Efficiency that consistently prioritizes risk-based, phase-appropriate maintenance and validation
- Technology innovation poised to boost productivity and improve facility use, as well as support comprehensive laboratory and manufacturing services
In this whitepaper, we explore each of these pillars in more detail.